An experimental drug created for killing or atleast slowing down the growth of Alzheimer's disease has also let the companies Johnson & Johnson and Pfizer down to touch the ground, a recent report finds.

It has been found that the drug named bapineuzumab had though passed in its initial tests, the same failed to prove beneficial for patients in a late-stage trial. An earlier trial for a similar drug had also failed; the news of failure in succession is thus more disappointing for the manufacturers.

The two have even decided to conduct no more trials for the drug, which was in its IV version, though a review of subcutaneous use would not be held back. The Irish business Elan is also in support of the companies saying there is no meaning to take the trial further.

No signs of improvements were found in patient participants taking a placebo or those on bapineuzumab. However, since it is an urgent need of the hour to address the disease affecting almost 36 million people each year in the US. Thus, a new drug is being planned to undergo a trial with more hopes to see it as a successful cure.

The drug dubbed solanezumab is being developed by Eli Lilly and would probably come up with results by late this year.